<DOC>
	<DOCNO>NCT01948986</DOCNO>
	<brief_summary>This study evaluate effect renal impairment pharmacokinetics , pharmacodynamics , safety tolerability ertugliflozin participant type 2 diabetes mellitus ( T2DM ) healthy participant normal renal function .</brief_summary>
	<brief_title>Effect Renal Impairment Pharmacokinetics , Pharmacodynamics , Safety Tolerability Ertugliflozin Participants With Type 2 Diabetes Mellitus ( MK-8835-009 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body Mass Index ( BMI ) approximately 18 40 kg/m^2 Stable renal function Male female reproductive potential Female reproductive potential must agree partner agree use 2 acceptable method contraception Healthy subject determine healthy investigator screen T2DM participant diagnosis T2DM per American Diabetes Association guideline T2DM participant stable antihyperglycemic regimen new drug drug dosage within 8 week study participation . Variations daily dose insulin 10 % permit . A positive urine drug screen drug abuse recreational drug Pregnant nursing female History abuse alcohol illicit drug Significant renal urinary disease within 6 month study participation History malignancy within past 5 year basal cell carcinoma skin cervical cancer situ History human immunodeficiency virus ( HIV ) History blood dyscrasia disorder cause hemolysis unstable red blood cell Any acute disease state ( eg , , vomit , fever , diarrhea ) within 7 day study participation Treatment investigational drug within 30 day study participation Use herbal supplement within 28 day prior study participation Any clinically significant malabsorption condition Blood donation ( exclude plasma donation ) approximately 1 pint within 56 day prior study participation History sensitivity ertugliflozin SodiumGlucose coTransporter 2 ( SGLT2 ) inhibitor History sensitivity heparin heparininduced thrombocytopenia Unwilling unable comply study Lifestyle Guidelines Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease include clinically relevant significant drug allergy Use prescription drug ( hormonal method birth control allow ) , vitamins dietary supplement within 7 day study participation For T2DM participant , history type 1 diabetes mellitus history ketoacidosis For T2DM participant , clinically significant electrocardiogram abnormality For T2DM participant , history myocardial infarction , unstable angina , coronary revascularization , stroke transient ischemic attack within 3 month study participation For T2DM participant , heart failure define New York Heart Association Functional Class IIIIV For T2DM participant , renal allograft recipient For T2DM participant , require dialysis For T2DM participant , strict fluid restriction For T2DM participant , urinary incontinence For T2DM participant , acute renal disease For T2DM participant , significant hepatic , cardiac , pulmonary disease clinically nephrotic For T2DM participant , prescription overthecounter medication take accord stable regimen 7 day study participation For T2DM participant , metformin enrol baseline renal function outside approved product label For T2DM participant receive follow medication within 7 day study participation : 1 . Other SGLT2 inhibitor ( eg , dapagliflozin , canagliflozin , empagliflozin ) ; 2 . Other injectable antihyperglycemic agent include pramlintide Glucagonlike peptide1 ( GLP1 ) analogues ; 3 . Any immunosuppressive drug , include cyclosporine , tacrolimus , sirolimus ; 4 . Oral corticosteroid ( note inhale , nasal topical corticosteroid permit ) ; 5 . Any potent drugmetabolizing enzymeinducing drug , include rifampin , phenytoin , carbamazepine ; 6 . Probenecid , valproic acid , gemfibrozil .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>